Finland· FI-REL-REL1664
Primaspan
A acetylsalicylic acid product, registered in Finland by Orion Corporation Orion Pharma. The same ATC class is registered in 13 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Acetylsalicylic acid is registered in 13 of 19 countries.
Countries holding a registration under ATC N02BA01 (acetylsalicylic acid), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Acetylsalicylic acid · ATC N02BA01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of acetylsalicylic acid costs, country by country.
Normalised to the WHO defined daily dose (3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Acetylsalicylic acid · price per daily dose (3 g)
USD · FX 28 Sept 2026
- CH Switzerland$2.31
The record
At a glance
Fimea (Finland)- Manufacturer
- Orion Corporation Orion Pharma
- Country
- Finland (FI)
- ATC code
- N02BA01
- ATC class
- Acetylsalicylic acid
- Defined daily dose
- 3 g, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
832 interactions on record for acetylsalicylic acid.
Graded by severity as the source publishes them — 55 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Acetylsalicylic acid · interactions on record
832 records
- 55 severe
- 246 moderate
- 39 minor
- 429 info
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- DalteparinB01AB04severe
- EnoxaparinB01AB05severe
63 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N02BA01
Acetylsalicylic acid, as other registers publish it.
- FinlandAcetardBenzon Pharma A/S
- FinlandAcetardBenzon Pharma A/S
- FinlandAcetardBenzon Pharma A/S
- NorwayAcetilsalicilato de Lisina labesfalLabesfal Laboratorios Almiro
- FinlandAcetylsalic.LeirasSchering Oy
- GermanyAcetylsalicylsäure AdgcZentiva Pharma Gmbh
- GermanyAcetylsalicylsäure G.L. PharmaG.L. Pharma Gmbh
- GermanyAcetylsalicylsäure I.V. PanpharmaPanmedica
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cf82cbb3-8f69-49be-a421-f96e2a453c53 GET /v1/drugs/cf82cbb3-8f69-49be-a421-f96e2a453c53?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "3",
"form": "enterotabletti",
"route": null,
"ddd_unit": "g",
"strength": "750 mg",
"atc_label": "asetyylisalisyylihappo",
"ma_number": "8668",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL1664",
"authorised_at": "1984-03-07"
}See everything about acetylsalicylic acid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.